First patients enrolled on the Veris Cancer
Care Platform
NEW
YORK, June 13, 2024 /PRNewswire/ -- PAVmed
Inc. (Nasdaq: PAVM) ("PAVmed" or the "Company") a diversified
commercial-stage medical technology company, operating in the
medical device, diagnostics, and digital health sectors, and its
majority-owned digital health subsidiary Veris Health Inc.
("Veris"), today announced that Veris and The Ohio State University Comprehensive Cancer Center –
Arthur G. James Cancer Hospital and Richard J. Solove Research
Institute (OSUCCC – James), a National Cancer Institute-Designated
Comprehensive Cancer Center, launched a pilot program and enrolled
the first patients on the Veris Cancer Care Platform™ pursuant to a
recently-executed memorandum of understanding.
"The OSUCCC – James is one of the largest academic cancer
centers in the nation and we couldn't be more excited to enroll our
first patients in a pilot program at such a renowned institution at
the forefront of cancer care," said James
Mitchell, M.D., Veris' Chief Medical Officer. "We look
forward to completing a successful pilot program and continuing to
execute our vision to offer enhanced personalized cancer care to
the thousands of patients who receive systemic cancer therapy at
the OSUCCC – James every year."
The Veris Cancer Care Platform is a comprehensive digital cancer
care platform with remote physiological data collection, symptom
reporting, telehealth capability, and electronic health record
integration. The platform seeks to offer enhanced personalized
cancer care through the early detection of complications, reduced
unplanned hospitalizations, the provision of longitudinal trends of
physiological and clinical data, data-driven risk management tools,
and increased patient and provider satisfaction.
Cancer patients enrolled on the platform receive a VerisBox™ of
Veris-branded connected health care devices which transmit
physiologic data to the cloud-based clinician portal via embedded
cellular connections. A complementary patient portal enables
patients to report symptoms, as well as general health and quality
of life parameters, to their cancer care team through the Veris
patient smartphone app. The app also allows patients to invite
caretakers and family members to follow along on their cancer care
journey. Veris is also developing an implantable physiological
monitor, designed to be implanted alongside a vascular access port,
which will interface with the Veris Cancer Care Platform. The
implantable monitor will further enhance the clinical and
commercial value of the platform by providing remote physiologic
data independent of patient compliance.
Cancer centers and oncology practices interested in learning
more about Veris and the Veris Platform, please visit
www.verishealth.com to contact a company representative.
About PAVmed and Veris
PAVmed Inc. is a diversified commercial-stage medical technology
company operating in the medical device, diagnostics, and digital
health sectors. Its majority-owned subsidiary, Veris Health Inc.,
is a digital health company whose lead product is a digital cancer
care platform with physiologic data collection, symptom reporting
and telehealth functions, designed to improve personalized cancer
care through remote patient monitoring. Veris has also been
developing an implantable physiological monitor, designed to be
implanted alongside a chemotherapy port, which will interface with
the Veris cancer care platform. Its other majority-owned
subsidiary, Lucid Diagnostics, is a commercial-stage cancer
prevention medical diagnostics company that markets the
EsoGuard® Esophageal DNA Test and EsoCheck®
Esophageal Cell Collection Device—the first and only commercial
tools for widespread early detection of esophageal precancer to
mitigate the risks of esophageal cancer deaths.
For more information about PAVmed, please
visit pavmed.com.
For more information about Veris Health, please visit
verishealth.com.
For more information about Lucid Diagnostics, please visit
luciddx.com.
To learn more about cancer treatment and clinical trials at the
OSUCCC – James, visit cancer.osu.edu.
Forward-Looking Statements
This press release includes forward-looking statements that
involve risk and uncertainties. Forward-looking statements are any
statements that are not historical facts. Such forward-looking
statements, which are based upon the current beliefs and
expectations of PAVmed's management, are subject to risks and
uncertainties, which could cause actual results to differ from the
forward-looking statements. Risks and uncertainties that may cause
such differences include, among other things, volatility in the
price of PAVmed's common stock; general economic and market
conditions; the uncertainties inherent in research and development,
including the cost and time required to advance PAVmed's products
to regulatory submission; whether regulatory authorities will be
satisfied with the design of and results from PAVmed's clinical and
preclinical studies; whether and when PAVmed's products are cleared
by regulatory authorities; market acceptance of PAVmed's products
once cleared and commercialized; PAVmed's ability to raise
additional funding as needed; and other competitive developments.
These factors are difficult or impossible to predict accurately and
many of them are beyond PAVmed's control. In addition, new risks
and uncertainties may arise from time to time and are difficult to
predict. For a further list and description of these and other
important risks and uncertainties that may affect PAVmed's future
operations, see Part I, Item 1A, "Risk Factors," in PAVmed's most
recent Annual Report on Form 10-K filed with the Securities and
Exchange Commission, as the same may be updated in Part II, Item
1A, "Risk Factors" in any Quarterly Report on Form 10-Q filed by
PAVmed after its most recent Annual Report. PAVmed disclaims
any intention or obligation to publicly update or revise any
forward-looking statement to reflect any change in its expectations
or in events, conditions, or circumstances on which those
expectations may be based, or that may affect the likelihood that
actual results will differ from those contained in the
forward-looking statements.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/pavmed-subsidiary-veris-health-announces-launch-of-pilot-program-with-the-ohio-state-university-comprehensive-cancer-center--james-cancer-hospital-and-solove-research-institute-302171570.html
SOURCE PAVmed Inc.